Article
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2007
Guo Tianhua, Agaram Narasimhan P, Wong Grace C, Hom Glory, D'Adamo David, Maki Robert G, Schwartz Gary K, Veach Darren, Clarkson Bayard D, Singer Samuel, DeMatteo Ronald P, Besmer Peter, Antonescu Cristina R
Abstract excerpt
PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain. We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly observed imatinib-resistant KIT mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.